Inventor

LERCHEN HANS-GEORG

DE48 patents

⚠️ This page may combine multiple inventors who share the name “LERCHEN HANS-GEORG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LERCHEN HANS-GEORG

Bayer Pharma AG

Site specific homogeneous with KSP inhibitors

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies

Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies

Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)

Antibody drug conjugates (ADCS) having enzymatically cleavable groups

Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups

Antibody drug conjugates (ADCs) having enzymatically cleavable groups

Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies

Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

Site specific homogeneous with KSP inhibitors

Antibody drug conjugates with enzymatically cleavable groups

Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies

Benzyl substituted indazoles as BUB1 inhibitors

Specific antibody drug conjugates (ADCs) having KSP inhibitors

Polyethylene glycol based prodrug of adrenomedullin and use thereof

Prodrug derivatives of substituted triazolopyridines

BAYER AG

Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage)

Octacyclodepsipeptides having an endoparasiticidal action

Octacyclodepsipeptides having an endoparasiticidal action

2,2&#39;-bridged bis-2,4-diaminoquinazolines

Octacyclodepsipeptides having an endoparasiticidal action

4, 4&#39;-bridged bis-2, 4-diaminoquinazolines

Octacyclodepsipeptides having an endoparasiticidal action

20(S) camptothecin glycoconjugates

Sugar-modified cytostatics

Glycoconjugates from modified camptothecin derivatives (20-O-linkage)

Cytostatic conjugates with integrin ligands

Prodrugs of cytotoxic active agents having enzymatically cleavable groups

Isotopically coded affinity markers 3

Integrin-mediated drug targeting

LERCHEN HANS-GEORG

Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders

N-carboxyalkylauristatins and use thereof

N-carboxyalkyl-auristatin and the use thereof

Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders

Dipeptoid prodrugs and the use thereof

Auristatin derivatives and use thereof

Dipeptoid prodrugs and the use thereof

BAYER IP GMBH

Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders

Dipeptoid prodrugs and their use

Tyrosine based linkers for the releasable connection of peptides

Polyethylene glycol based prodrug of adrenomedullin and use thereof

Polyethylene glycol based prodrug of adrenomedullin and use thereof

SEATTLE GENETICS INC

Binder-drug conjugates (ADCs) and use thereof

(unassigned)

Trioxane derivatives

VAKALOPOULOS ALEXANDROS

Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs

KLAR JÜRGEN

Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

2,2'-bridged bis-2,4-diaminoquinazolines

4, 4'-bridged bis-2, 4-diaminoquinazolines